Today's Hours: 8:00am - 6:00pm

Search

Did You Mean:

Search Results

  • Book
    editors Richard A. Rudick, Robert A. Bermel.
    Contents:
    Addressing unmet medical needs in RR-MS / Robert A. Bermel & Richard A. Rudick
    Current guidelines and standard treatments of RR-MS / R. Philip Kinkel & Augusto Miravalle
    Oral agents for the treatment of RR-MS / Douglas R. Jeffery
    Monoclonal antibodies / Jennifer Graves & Emmanuelle L. Waubant
    Other therapeutics in the pipeline and future directions / Yuval Karmon, Bijal K. Mehta & Bianca Weinstock-Guttman.
    Digital Access Future Med 2011
  • Article
    Donofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J.
    J Clin Invest. 1978 Oct;62(4):884-7.
    The deoxynucleotide, dATP, is elevated 50- to 1,000-fold above normal in erythrocytes, lymphocytes, and bone marrow from a child with adenosine deaminase deficiency and severe combined immunodeficiency disease. The child, when 17 mo of age, was also excreting approximately 30 mg of deoxyadenosine per day in urine (normal is less than 0.1 mg/day). Urinary excretion of uric acid was decreased. Elevated dATP levels in lymphocytes and bone marrow, and increased urinary excretion of deoxyadenosine, persisted despite hypertransfusion of the child with irradiated erythrocytes from a donor with normal adenosine deaminase. Overproduction of deoxynucleotides by increased salvage of adenosine appears to be the primary metabolic abnormality in patients with adenosine de aminase deficiency.
    Digital Access Access Options